NASDAQ:IMVT 20 May 2026

Roivant stock set for new test after big move on drug data

Roivant stock set for new test after big move on drug data

Roivant Sciences shares traded up in quiet premarket action Tuesday, showing a move after last week’s jump on drug data and the U.S. market holiday. The Nasdaq stock stood at $30.31 before the open, gaining 1.2% from Friday’s $29.96 close, with just 384 shares changing hands early. Timing is key. U.S. stock markets were shut for Memorial Day on Monday. Nasdaq’s regular hours are 9:30 a.m. to 4 p.m. Eastern, with premarket trading from 4 a.m. to 9:30 a.m. Eastern. Premarket is outside the main session and usually sees lighter liquidity.
May 26, 2026
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data

argenx SE’s U.S. shares inched up Wednesday, trailing the biotech sector after Immunovant released rheumatoid-arthritis data that drew new focus to the same drug class as argenx’s VYVGART franchise. ARGX was trading at $803.67 near the end of the session, up 0.7%. The iShares Nasdaq Biotechnology ETF added 2.1% and SPDR S&P Biotech ETF climbed 3.8%. Shares of Immunovant soared 35.1%. Roivant Sciences, Immunovant’s parent, rose 14.6%, according to market data.
May 20, 2026